Background Ibrutinib, an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an eff ective treatment for relapsed chronic lymphocytic leukaemia (CLL). We investigated the activity and safety of the combination of ibrutinib with the monoclonal antibody rituximab in patients with high-risk CLL.
Introduction
Treatment of patients with chronic lymphocytic leukaemia (CLL) is undergoing major changes 1 because of the emergence of new treatment approaches, such as kinase inhibitors targeting B-cell receptor signalling 2, 3 and novel monoclonal antibodies. 4 Patients with CLL with high-risk cytogenetic abnormalities (deletion 17p, TP53 mutation, or deletion 11q) 5 can especially benefi t from new kinase inhibitors, in view of the high proportion of responses noted in patients treated with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib 2 and the PI3Kδ inhibitor idelalisib in combination with rituximab. 3 Chemo immunotherapy regimens, such as fl udarabine, cyclophosphamide, and rituximab, 6 or bendamustine in combination with rituximab, 7 are eff ective options for younger patients with lower risk CLL. However, patients with del(17p) or TP53 mutations respond poorly to chemoimmunotherapy, typically have short periods of remission, 6, 7 and consequently a short median life expectancy of only 2-3 years after fi rst-line therapy. 8 Patients with relapsed CLL and del(11q), who often have extensive lymphadenopathy, 9 also have a poor prognosis. These patients respond quite well to chemoimmunotherapy regimens, but have shorter remissions than do low-risk patients. 9, 10 Finally, patients with CLL who relapse early after fi rst-line chemo immunotherapy (ie, after <24-36 months) are another challenging group of high-risk patients 8, 10 with a low proportion of responses and short survival times when retreated with chemoimmunotherapy. 8, 10 Ibrutinib (previously called PCI-32765) is a potent (IC 50 0·5 nmol/L) selective BTK inhibitor that inactivates BTK through irreversible covalent bonding to Cys-481 in the ATP-binding domain of the kinase. 11 Ibrutinib is given to patients with CLL once daily orally at a fi xed dose of 420 mg continuously until disease progression or toxicity. Early-stage clinical trials showed single-agent ibrutinib to be especially active in patients with CLL 2, 12 and mantle cell lymphoma. 13 The CLL data are based on a phase 1b-2 multicentre study of ibrutinib in 85 patients with relapsed or refractory CLL or small lymphocytic lymphoma. 2 The authors reported a complete or partial response in 60 (71%) of 85 patients, and an additional fi ve (15%) of 34 patients in the 840 mg cohort and ten (20%) of 51 in the 420 mg cohort had a partial response with lymphocytosis. The responses were independent of clinical and genomic risk factors present before treatment, including advanced-stage disease, number of previous treatments, or presence of 17p deletion. At 26 months, the estimated progression-free survival (PFS) was 75% and overall survival was 83%. The results from this study led the US Food and Drug Administration (FDA) to designate ibrutinib as a breakthrough therapy in patients with CLL with del(17p) and their approval of single-agent ibrutinib for previously treated patients with CLL in February, 2014.
14 In another recent randomised trial, 15 investigators compared ibrutinib with the anti-CD20 antibody ofatumumab in patients with relapsed or refractory CLL or small lymphocytic lymphoma. Objective responses were signifi cantly more common in the ibrutinib group (43%) than in the ofatumumab group (4%). A further 20% of ibrutinib-treated patients had a partial response with lymphocytosis. At a median followup of 9·4 months, ibrutinib signifi cantly improved PFS and overall survival when compared with ofatumumab. 15 In patients with CLL, ibrutinib mobilises leukaemia cells from tissue sites into the peripheral blood, 16 resulting in lymphocytosis during the fi rst few weeks of treatment, which is variable among patients and is directly related to the presence of the drug. On an intermittent dosing schedule, a raised absolute lymphocyte count rapidly dropped during the offibrutinib period, presumably because of increased tissue homing, and then increased again when ibrutinib treatment was restarted. 12 This lymphocytosis is asymptomatic and normalises after a median of 6·2 months. 17 It is caused by the re-distribution of CLL cells from the tissue compartments into the peripheral blood 12, 16 rather than by disease progression. Preclinical models show that ibrutinib inhibits CLL cell survival and proliferation, 18 and leukaemia cell migration towards tissue-homing chemokines (CXCL12 and CXCL13) and integrin-mediated CLL cell adhesion; 19, 20 this process resulted in transient redistribution lymphocytosis into the peripheral blood in an adoptive transfer CLL mouse model. 19 In view of this redistribution with single-agent ibrutinib, which can persist in many patients, the wellrecognised effi cacy of rituximab in clearing leukaemia cells from the peripheral blood, and the documented benefi t of rituximab in chemotherapy combinations on PFS and overall survival in untreated patients with CLL, 6 we explored the safety and activity of the combination of ibrutinib and rituximab in patients with high-risk CLL.
Methods

Study design and participants
Adult patients with high-risk CLL or small lymphocytic lymphoma were eligible for enrolment in this single-arm, phase 2 study. Patients had to be aged 18 years or older and have previously treated high-risk CLL or untreated CLL with del(17p) or TP53 mutation. High-risk CLL was defi ned by the presence of a 17p deletion, TP53 mutation, or 11q deletion, according to the hierarchical cytogenetic model developed by Dohner and colleagues. 5 Patients with CLL and small lymphocytic lymphoma who had short remission durations of less than 36 months after previous fi rst-line chemoimmunotherapy also fulfi lled criteria for high-risk disease. Patients with a 17p deletion or TP53 mutation were not required to have received previous treatment because of the poor outcome of such patients with chemoimmunotherapy. For previously treated patients, a 30-day washout period since previous therapy was required. Patients had to have an indication for therapy in accordance with the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria, 21 adequate renal and hepatic function (defi ned by an estimated creatinine clearance of >30 mL/min), an alanine aminotransferase concentration of no more than 2·5 times the upper limit of the normal range, and no active infection. Patients with uncontrolled autoimmune haemo lytic anaemia or autoimmune thrombocytopenia, severe hematopoietic insuffi ciency (absolute neutrophil count <0·5 × 10⁹ cells per L and/or platelet count <30 × 10⁹ cells per L), bleeding diathesis or coagulopathy, recent haemorrhagic events or surgery, and those receiving concomitant treatment with warfarin, were excluded.
This trial was approved by the University of Texas MD Anderson Cancer Center institutional review board. Written informed consent was obtained from all patients in accordance with institutional guidelines and the Declaration of Helsinki.
Procedures
Pretreatment assessment of participants included complete medical history; physical examination; complete blood count with diff erential white blood cell count; and chemistry profi le assessment of serum creatinine, electrolytes, albumin, calcium, uric acid, lactate dehydrogenase, and alanine aminotransferase. We also measured concentrations of serum immunoglobulins and β 2 -microglobulin, and analysed the peripheral T-cell lymphocyte subset by fl ow cytometry. We did bone marrow aspiration before treatment, including infi ltration assessment, immuno phenotype by fl ow cytometry, and immuno globulin heavy chain gene mutation analysis by PCR. Standard metaphase karyotype analysis and genomic abnormalities were detected by fl uorescence in-situ hybridisation with standard CLL probes (Abbott Molecular, Des Plaines, IL, USA).
Treatment consisted of oral ibrutinib 420 mg continuously daily (one cycle was 28 days), in combination with weekly rituximab (375 mg/m² intravenously) for weeks 1-4 (cycle 1) to front-load during the time of highest intravascular CLL cell burden, and then rituximab was given once every 4 weeks until cycle 6, followed by singleagent ibrutinib 420 mg continuously daily. Patients remained on treatment until disease progression or until toxicities or complications precluded further treatment, whichever occurred fi rst. In the event of any grade 3-4 toxicity, ibrutinib was stopped until the adverse event returned to baseline or resolved completely. In the event of any grade 4 toxicity or for any rituximab-related, clinically signifi cant, unmanageable grade 3 adverse events, rituximab was withheld until the adverse event returned to baseline or resolved completely. Dose modifi cations were not allowed. Clinical and laboratory assessments were done every week during cycle 1, then once every 4 weeks until cycle 6, and then every 3 months thereafter while patients remained on study. Clinical assessments included radiological examinations with CT scans of the chest, abdomen, and pelvis at baseline. Bone marrow aspirations and biopsies were undertaken and assessed by morphology and fl ow cytometry at baseline and after 3, 6, and 12 months, and once every 12 months thereafter. Minimal residual disease was assessed with four-colour fl ow cytometry. Quantitative minimal residual disease results were categorised as positive (≥0·01%) or negative (<0·01%). 22 Safety monitoring was done weekly for the fi rst month, then monthly until month 6, and every 3 months thereafter. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Haematological toxic eff ects were graded according to the IWCLL system. 21 The European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire was used to assess health-related quality of life, as detailed in appendix p 1.
We tested BTK target occupancy during ibrutinib and rituximab treatment using a fl uorescently tagged derivative of ibrutinib (PCI-33380). Chemotaxis of CLL cells was assayed across polycarbonate Transwell inserts (Corning Incorporated Life Sciences, Tewksbury, MA, USA). We assessed plasma concentrations of CCL3 and CCL4 before and during treatment by ELISA using Quantikine kits (R&D Systems, Minneapolis, MN, USA). For all other cytokines, we used multiplex bead assays according to the manufacturer's instructions (EMD Millipore, Billerica, MA, USA). For gene-expression analyses, we isolated RNA from CD19-purifi ed CLL cells from the peripheral blood of ten randomly selected patients, collected at baseline and after 7 and 28 days on ibrutinib and rituximab combination treatment. We tested gene expression with HG U133 plus 2.0 oligonucleotide arrays from Aff ymetrix (Santa Clara, CA, USA) in eight patients samples (two patients had insuffi cient amounts of RNA), following Aff ymetrix standard protocols. Further details are provided in appendix pp 1-2.
Outcomes
The primary endpoint was PFS, which was defi ned as the time between initiation of study treatment and the date of fi rst documented disease progression or death from any cause. Secondary endpoints were overall survival, the proportion of patients with an overall response, and responses and survival in cytogenetic subgroups, rates of treatment-related and unrelated adverse events, quality of life, and changes in correlative biomarkers during treatment. We assessed responses according to the IWCLL criteria, 21 with the exception that lymphocytosis was not the sole criterion for disease progression. 
Data are median (range) or n (%). To assess for disease progression on treatment, the best response-ie, the true nadir-was considered as baseline. For example, if a patient had normalisation or major reduction of absolute lymphocyte count on ibrutinib and rituximab therapy, but later developed progressive lymphocytosis, this patient would be judged to have progressive disease, especially in the context of other signs (clinical and laboratory) of disease progression, such as progressive cytopenias, increasing amounts of lactate dehydrogenase, organomegaly, progressive lymphadenopathy, or all of these signs.
Statistical analysis
We established that a sample size of 40 patients would give us power of at least 80% to determine that the combination of rituximab and ibrutinib improves the PFS in high-risk CLL by 2 months when compared with available data for a similar group of patients treated with standard chemoimmunotherapy. 10 PFS was monitored continuously, and accrual was to have been terminated early if the probability of improving PFS by 2 months was less than 0·01. The Department of Biostatistics at the MD Anderson Cancer Center provided and maintained a website for enrolment of patients into this study and for the continuous evaluation of PFS.
We used descriptive statistics to summarise the patient cohorts at predefi ned timepoints. We used Fisher's exact test and Wilcoxon rank test in the univariate analyses to compare groups. We used the Wilcoxon signed-rank test for paired data to establish whether there were diff erences in the distribution between timepoints in the quality-of-life outcomes. The safety analysis was done based on the intent-to-treat population, whereas the effi cacy analysis was done using only the evaluable cohort (ie, patients with suffi cient follow-up of at least 3 months). Toxicity was reported by type, frequency, and severity. We tabulated the worst toxicity grades per patient for selected adverse events and laboratory measurements. We estimated survival with the Kaplan-Meier method. Patients were censored for PFS at the last clinical assessment before receipt of new antileukaemia treatment, or after loss to follow-up, whichever occurred fi rst. Patients were censored for overall survival at the last known alive date.
STATA/SE version 12.1 and GraphPad Prism version 6.00 for Windows were used for statistical analyses. This study is registered with ClinicalTrials.gov, number NCT01520519.
Role of the funding source
The study was supported by Pharmacyclics Inc. Together with Pharmacyclics, the clinical investigators were responsible for the design of the study protocol and analysis plan. The investigators and their research teams gathered, compiled, and analysed all the data. The investigators had full access to the data and analyses for compilation of this report. JAB wrote the fi rst draft, which was carefully reviewed by Pharmacyclics Inc and all coauthors, who approved the fi nal submitted version. The corresponding author had full access to all the data and had fi nal responsibility to submit for publication.
Results
Between Feb 28, 2012, and Sept 11, 2012, 40 patients were enrolled at the MD Anderson Cancer Center, of whom 36 had previously treated high-risk CLL and four had del(17p) or TP53 mutation and were previously untreated. This analysis shows the fi nal data from our study, which we extracted on Nov 18, 2013. Table 1 summarises the baseline characteristics. At a median follow-up of 16·8 months (IQR 2·3-20·5), 31 patients continued on therapy (including 14 of the 20 with del[17p] or TP53 mutation) and nine (22·5%) discontinued treatment. Of the nine patients who discontinued, two died during the study and six died after study discontinuation. One patient who died during the study had an unrelated infectious complication (pneumonia and CNS abscesses) during the second cycle of treatment, and the other patient died when in remission from an unknown cause. The six other patients who died after study discontinuation died from infectious complications or disease progression (see appendix p 4 for details). Two patients (5%) discontinued treatment because of toxicity (one grade 3 mucositis and one grade 3 recurrent ear and pulmonary infections) after fi ve cycles and after two cycles, respectively. One patient stopped treatment because of resistant pneumonia and another because of progressive chronic obstructive pulmonary disease. Three (8%) patients had disease progression after 176, 395, and 429 days, one of whom had Richter's transformation. The post-remission treatments are detailed in appendix p 4. 39 patients were evaluable for response assessment according to 2008 IWCLL guidelines, whereas one was not evaluable because the follow-up was too short (<3 months). 34 (87%) achieved partial remission, and three (8%) complete remission as their best response; thus 37 (95%) of patients had an overall response. Two patients did not respond to treatment: these were the two patients who discontinued treatment early. Two of the three patients Functioning scale
Single-item scale
Data derived from various measures on the EORTC quality of life questionnaire C30 version 3. p values correspond to comparison of Z scores. Signifi cant improvements occurred in global health status, functioning, and symptom scales, and other single items (insomnia, appetite loss, and dyspnoea). Table 2 : Quality of life at baseline and after 6 months of treatment with ibrutinib and rituximab who achieved complete remission had del(17p) or TP53 mutation and were previously untreated. One patient in complete remission was negative for minimal residual disease by fl ow cytometry. 16 partial remissions and two complete remissions were noted in the 20 patients with del(17p) or TP53 mutation. The median time to achieve a response was 5·72 months (IQR 5·32-6·87), and the median duration of response was 15·44 months (10·55-18·27). In the 38 patients evaluable for lymphocyte count, blood lymphocytosis peaked at a median of 1 week of combination therapy, and then decreased continuously (fi gure 1A). Lymphocyte count normalised (absolute lymphocyte count <4 × 10⁹ cells per L) after 7 months (fi gure 1A). CT scans at 6 months and 12 months showed a greater than 50% reduction in lymphadenopathy in 29 (85%) of the 34 patients with measurable lesions both at and after baseline, and that all 34 patients had improvements in lymphadenopathy (fi gure 1B). Notable reductions were also recorded in spleen size (appendix p 18). Serial bone marrow assessments showed a signifi cant decrease in bone marrow infi ltration by CLL cells (fi gure 1C).
18-month PFS for all patients was 78·0% (95% CI 60·6-88·5); in patients with del(17p) or TP53 mutation, 18-month PFS was 72·4% (45·6-87·6). 18-month overall survival was 83·8% (95% CI 67·2-92·4) for all patients, whereas for patients with del(17p) or TP53 mutation, it was 78·4% (52·0-91·4, fi gure 2).
Sustained improvement in cytopenias, defi ned as improvement by more than 50% from baseline or a haemoglobin concentration higher than 110 g/L, or a platelet count higher than 100 × 10⁹ cells per L lasting for at least two cycles without transfusion or administration of growth factors, was noted in 15 (63%) of 24 patients with baseline thrombocytopenia, and 15 (88%) of 17 with anaemia (appendix p 19). Because of the early resolution of lymphocytosis, cases of partial remissions with lymphocytosis were rare at early timepoints (three [8%] patients after six cycles) and absent after 12 months of treatment.
In a comparison of diff erences in health-related quality of life between baseline and during treatment, we noted that patients who received ibrutinib and rituximab showed signifi cant improvements in overall health and quality of life after 6 and 12 months (table 2, and appendix p 3), which coincided with a signifi cant weight gain at 3 and 6 months (appendix p 20).
Overall, treatment was well tolerated, with respiratory infections (11 cases of pneumonia [grade 2 or 3] and ten cases of upper respiratory infections [grade 2] and one grade 3 upper respiratory infection) being the most common adverse events. Possibly treatment-related grade 1-3 adverse events of mucositis (in three patients) and peripheral neuropathy (three patients) also occurred. One grade 3 subdural hematoma occurred in a 70-year-old man, who fell and subsequently developed headaches. This patient did not require any intervention; ibrutinib was initially withheld, and later restarted. Milder toxicities included grade 1-2 diarrhoea (n=10); bruising and rash (n=13); nausea, vomiting, or acid refl ux (n=15); fatigue (n=7); and bone pain, myalgia, or arthralgia (n=11). Haematological toxicities included grade 3-4 neutropenia (n=2) and grade 2 anaemia (n=2). The toxicities are summarised in table 3 and appendix p 21; appendix p 5 shows toxicities stratifi ed by whether or not they were judged to be treatment related.
We recorded a relatively homogeneous gene-expression response of CLL cells during combination therapy. Appendix p 23 shows heatmaps that illustrate the most downregulated genes in CLL cells after 7 days and 28 days of treatment compared with baseline gene expression. The genes with known and potentially relevant function are annotated on appendix p 23, and include the chemokine CCL3; EGR1, 2, and 3; and CD72. We provide more details in the appendix pp 6-17, where we display the most upregulated and downregulated genes after 7 days and 28 days of therapy.
Mean β 2 -microglobulin concentration in the 40 patients before treatment was 5·2 mg/L (SE 0·43), and decreased signifi cantly during ibrutinib and rituximab treatment to 3·2 mg/L (SE 0·22) after 3 months (n=37), to 2·9 mg/L (0·21) after 6 months (n=35), to 2·5 mg/L (0·15) after Appendix p 22 provides T-cell counts in individual patients before and during ibrutinib and rituximab therapy. The combination of ibrutinib and rituximab resulted in full occupancy of BTK at both timepoints assessed (ie, after 7 and 14 days of treatment; appendix p 24). To explore the eff ects of this treatment on CLL cell migration in vivo, we tested serial blood CLL samples in chemotaxis assays. The combination of ibrutinib and rituximab signifi cantly reduced CLL cell chemotaxis towards CXCL12 and CXCL13 (appendix p 24). For example, the mean relative numbers of CLL cells from six patients migrating toward CXCL13 decreased from 1906 (SE 556) before therapy to 666 (133) after 14 days, and 1109 (401) after 28 days of treatment.
We assayed serial plasma samples for changes in cytokines and chemokines at earlier timepoints (after 14 and 28 days) and at a later timepoint (after 90 days). We C recorded signifi cant reductions in plasma concentrations of several cytokines that are either derived from CLL cells (CCL3 and CCL4) or originate from cells in the microenvironment (CXCL13). For example, after 14 days and 28 days of ibrutinib and rituximab treatment, raised median plasma concentrations of CCL3 decreased signifi cantly from 139·6 (SE 40·4) to 6·9 (0·9) pg/mL, and concentrations of CCL4 fell from 578·6 (SE 103·9) to 68·7 (7·2) pg/mL (appendix p 24). Plasma concentrations of CCL19 TNFα (appendix p 24) and CCL21 (data not shown) were also signifi cantly reduced after 1 month. CXCL13 plasma concentrations decreased signifi cantly from 94·6 (SE 16·3) pg/mL to 32·26 (6·9) pg/mL after 1 month and to 28·7 (SE 6·8) pg/mL after 3 months of ibrutinib and rituximab. Concentrations of CXCL12 remained stable during treatment (appendix p 24).
Discussion
The combination of ibrutinib and rituximab induced responses in a large proportion of patients with high-risk CLL. Responses were durable, and 78% of patients were free of disease progression and 84% still alive at 18 months.
Although cross-trial comparisons have obvious limitations (panel), one of the most notable fi ndings in this study is the short duration of ibrutinib-associated redistribution lymphocytosis. Fewer patients had persistent lymphocytosis than with single-agent treatment, 2 even at early timepoints, presumably caused by the addition of rituximab. 20% of patients treated with 420 mg ibrutinib daily as single agent in other trials had persistent lymphocytosis at 12 months, 2,17 by contrast, persistent lymphocytosis was rare after 6 months of ibrutinib and rituximab (8%), and absent after 12 months. Similar fi ndings of a blunted and shortened duration of lymphocytosis were recently reported for the combination of the PI3Kδ inhibitor idelalisib with rituximab in patients with relapsed CLL. 3 Additionally, compared with the reported single-agent experience, objective remissions were achieved in more patients. 2, 15 The relevance of clearance of CLL cells from the peripheral blood during ibrutinib therapy remains largely unknown. Woyach and colleagues 17 recently published data showing that persistent lymphocytosis during ibrutinib therapy was not associated with an adverse outcome, which suggests that elimination of CLL cells from the peripheral blood-traditionally a key response criterion-might not be a necessary goal of ibrutinib-based treatment. In this study, we assessed the activity of ibrutinib in combination with rituximab. Rituximab, which has very low clinical activity in CLL as a single agent, substantially increases PFS and overall survival when added to fl udarabine and cyclophosphamide in previously untreated patients with CLL. 6, 23 Its role as combination partner with ibrutinib, beyond eff ective clearance of CLL cells from the peripheral blood, cannot be further defi ned in this study and is now being addressed in an ongoing randomised trial of ibrutinib versus the combination of ibrutinib and rituximab (NCT02007044) for patients with relapsed CLL (also including previously untreated patients with highrisk CLL with del[17p] or TP53 mutation).
In addition to BTK, ibrutinib can also interfere with the activity of other kinases that contain a modifi able cysteine residue homologous to Cys-481 in BTK, such as interleukin-2 inducible tyrosine kinase. 27 This kinase is expressed in natural killer and T cells, and Kohrt and colleagues 28 recently reported that ibrutinib antagonises rituximab's anti-lymphoma activity in a mouse model, based on ibrutinib's inhibition of FcR-stimulated natural killer cell function-specifi cally antibody-dependent cellmediated cytotoxicity. However, the relative contribution and importance of natural killer cells, monocytes, or other eff ector cells for CD20 antibody-mediated killing of B cells remains controversial. Other mechanisms of rituximabinduced toxicity towards malignant B cells, which are independent of natural killer cell function (through induction of direct cell death and complement-dependent cytotoxicity) have been documented. 29 The rapid clearance of CLL cells from the peripheral blood in this trial suggests that any antagonistic activity of ibrutinib does not have a signifi cant role in bloodstream clearance of CLL cells. Beyond this idea, to defi ne whether the addition of rituximab aff ects PFS or overall survival, we will need to wait for mature data from the randomised trial of ibrutinib versus ibrutinib and rituximab. If PFS or overall survival are prolonged with the addition of rituximab, this would suggest an absence of ibrutinib-rituximab antagonism in CLL in human beings.
The PFS and overall survival outcomes of our study compare favourably with other treatment options for similarly high-risk patients with CLL, especially in the relapsed disease setting (panel). In a retrospective singlecentre analysis of 174 patients, median PFS and overall survival in aff ected patients with del(17p) was higher with ibrutinib than with any other treatment, 30 and the high proportion of responses recorded in this study supports the conclusion that, of the approved therapies, ibrutinib alone or in combination with rituximab is a highly eff ective treatment for high-risk CLL. Besides PFS and overall survival, improvement in quality of life has become one of the major endpoints in clinical trials of novel anticancer drugs, especially in incurable diseases. CLL has a major eff ect on quality of life, which is especially poor in older patients, those with advanced-stage disease, fatigue, co-morbidity, and those who are receiving active treatment. 31 Eichhorst and colleagues 32 reported moderate improvement in quality of life after treatment with fl udarabine and cyclophosphamide. Our fi nding of a signifi cant improvement in quality of life during treatment with ibrutinib and rituximab supports the notion that eff ective treatment of CLL improves quality of life.
The gene-expression profi le data (appendix p 23) show on-target downregulation of B-cell receptor-regulated and NFκB-regulated genes that are believed to be central for CLL cell survival and interactions within the lymphoid tissue microenvironment. 33 For example, the chemokine CCL3, which is upregulated in CLL cells after nurse-like cell co-culture and after B-cell receptor triggering, 34 can attract accessory cells, such as T cells and monocytes, into the lymphoid tissues, fostering the infl ux of cells that support the survival and growth of the CLL clone. Leukaemia cells isolated from CLL lymph nodes contain high amounts of CCL3, 33 and high CCL3 plasma concentrations are predictive of a poor outcome in this cancer. 35 Importantly, down-modulation of CCL3 during ibrutinib and rituximab combination therapy occurred at the gene expression level and in patients' plasma samples, which serves as a cross-validation of the data and corroborates the value of CCL3 as a plasma biomarker for responses to kinase inhibitors that target B-cell receptor signalling, such as ibrutinib 19 and idelalisib. 36 The biologically most interesting correlative fi ndings in this study are the normalisation of high peripheral blood T-cell counts and of the concentrations of several cytokines, chemokines, and β 2 -microglobulin. T-cell numbers of both the CD4 and CD8 subsets are increased in untreated patients with CLL, and the normalisation of these cell populations during ibrutinib and rituximab therapy (fi gure 3) can be interpreted as a sign of co-evolution and interdependence between T cells and leukaemia cells. Signifi cant reductions in plasma levels of TNFα, the lymph node-homing chemokines CCL19 and CXCL13, and β 2 -microglobulin (appendix p 24) provide further insight into the targets and consequences of ibrutinib and rituximab therapy. Together with the inhibition of chemotaxis of CLL cells isolated from patients on this combination treatment (appendix p 24), which was expected from preclinical work 19, 20 and which is due to the direct eff ects of BTK inhibition on chemokine receptor signalling, 19, 20 the decrease in CCL19 and CXCL13 plasma levels (appendix p 24) points towards additional mechanisms for redistribution of tissue leukaemia cells into the peripheral blood during ibrutinib therapy. CCL19 and CXCL13 are important chemokines that coordinate normal and malignant B-cell homing into secondary lymphoid tissues, 37 and their downmodulation during ibrutinib and rituximab combination therapy could be an additional, indirect mechanism for CLL cell mobilisation by ibrutinib. Signifi cant reductions of raised TNFα and β 2 -microglobulin concentrations support the important role of these proteins in disease progression and prognosis, but no data exist to suggest a mechanism of regulation of these proteins by the combination of ibrutinib and rituximab.
The main strength of our study is a comprehensive set of clinical and correlative data that show safety and exceptionally high rates of responses with the combination of ibrutinib and rituximab in patients with CLL who have high-risk disease features. These fi ndings are of great interest for this diffi cult-to-treat patient population, which is in particular need of new treatment options. However, because of the non-randomised approach in this phase 2 trial, we cannot make any defi nitive conclusions about the , to identify studies of drugs used to treat patients with high-risk CLL (alemtuzumab, chlorambucil, rituximab, ofatumumab, obinutuzumab, fl udarabine, cyclophosphamide, and lenalidomide). We identifi ed primary publications for these agents 6, 8, 23, 24 that show that low proportions of patients respond to treatment and short remissions are a major problem. A number of trials of single-agent ibrutinib trials have been published. 12, 15, 25, 26 To our knowledge, no other data for ibrutinib combination therapy are yet available.
Interpretation
Our data suggest that the combination of ibrutinib and rituximab is active and safe for the treatment of patients with high-risk CLL. A randomised study of ibrutinib versus ibrutinib plus rituximab is ongoing (NCT02007044) and will establish whether the addition of rituximab, improves survival outcomes for patients with CLL. This ongoing trial is for patients with CLL with relapsed disease, but also includes previously untreated patients with high-risk CLL with del(17p) or TP53 mutation.
added benefi t of rituximab. Hence, a general recommendation for use of ibrutinib in combination with rituximab cannot be made at this time, until data from a randomised trial (ibrutinib versus ibrutinib plus rituximab) are available. The correlative data show ontarget down-modulation of BCR-regulated genes (eg, CCL3), normalisation of raised T cell numbers and other markers of CLL disease activity (eg, β 2 -microglobulin), and stable immuno globulin levels (except for IgM levels, which trended downwards). These correlative fi ndings provide a fascinating insight into regulatory circuits that govern CLL disease biology, and how these circuits are thwarted by targeted treatment. Several of these mechanisms probably also apply to other related mature B-cell malignancies, in which ibrutinib therapy, alone or in combinations, is currently being explored.
In summary, our fi ndings show that the combination of ibrutinib and rituximab is an active therapy for patients with high-risk CLL, in whom it induces a high proportion of objective responses and durable remissions in most patients. Treatment is well tolerated and is associated with signifi cant improvements in quality of life. A randomised study of ibrutinib versus ibrutinib plus rituximab is ongoing (NCT02007044) and will establish whether the addition of rituximab, besides abridging the initial lymphocytosis, improves PFS, overall survival, or both.
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